PEN · Penumbra Inc
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Global embolization and access revenue | 131.1M | the second quarter of 2026 | — |
| Global thrombectomy revenue | 259M | the second quarter of 2026 | — |
| Gross profit margin | 67.9% | the second quarter of 2026 | — |
| adjusted EBITDA non-GAAP | $266.8M | the full year 2025 | — |
| adjusted EBITDA margin non-GAAP | 19% | the full year 2025 | — |
| Non-GAAP diluted EPS non-GAAP | $3.84 | Year Ended December 31, 2025 | — |
| Non-GAAP income from operations non-GAAP | $189.25M | Year Ended December 31, 2025 | — |
| Non-GAAP net income non-GAAP | $150.88M | Year Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PEN
this stock
Penumbra Inc
|
$12.72B | +3.9% | +17.5% | 79.4 | 4.6% |
|
ABT
Abbott Laboratories
|
$198.74B | -8.9% | +5.7% | 32.0 | 1.2% |
|
SYK
Stryker Corp
|
$126.45B | -6.2% | +11.2% | 34.2 | 1.8% |
|
MDT
Medtronic plc
|
$117.57B | -4.2% | +8.4% | 24.6 | 1.1% |
|
BSX
Boston Scientific Corp
|
$68.44B | -49.5% | +12.5% | 19.1 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PEN | -1.2% | +0.9% | -5.2% | +0.6% | +3.9% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -0.8% | -4.1% | -17.6% | -2.0% | -8.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.